Atopic DermatitisFeatured PodcastPodcast Highlights

AD Treatment – The Future Landscape

By April 13, 2021April 15th, 2021No Comments

JDD Multimedia

JDD Podcast

Listen Now

How to Listen

AD Treatment – The Future Landscape

Drs. Amy Paller, Jonathan Silverberg & Adam Friedman

 

Consider this final episode of the 5 part all you can handle Atopic Dermatitis series the world series of dermatitis. Hall of famers Dr.s Amy Paller and Jonathan Silverberg join host Dr. Adam Friedman to review current moderate to severe AD treatment approaches and use of systemic therapies, discuss advancement on AD clinical management with use of novel target therapy, and share clinical experience with the use of biologics treatment. As we have all been thrown a curve ball in life, faculty address the growing concerns surrounding dermatology-related immunosuppressant therapy during the pandemic and how to discuss this issue with patients. Slide into home with a peak at the future therapies landscape in clinical development. The practical peals alone are worth the price of admission (um, it’s free).
Listen Now
Learning Objectives
Upon completion of this podcast participants should be able to:
  • Recognize the impact of target therapeutic in managing moderate to severe AD
  • Consider future treatment strategies that may enhance optimal patient care

This podcast is supported by an independent medical education grant provided by Sanofi Genzyme & Regeneron Pharmaceuticals.

Disclosures
Amy Paller, MD – Grant/Research Support: AbbVie, Eli Lilly, Regeneron. Incyte. Consultant: Abbvie, Arena, Bausch, Bristol Myer Squibb, Dermavant, Eli Lilly, Forte, Leo, Lifemax, Pfizer, Rapt, Regeneron, and Sanofi.

Jonathan Silverberg, MD – Grant/Research Support: Galderma, Pfizer. Consultant: Abbvie, Afyx, Arena, Asana, BioMX, Bluefin, Bodewell, Boehringer-Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo, Luna, Menlo, Novartis, Pfizer, RAPT, Regeneron, Sanofi. Speakers’ Bureau: Regeneron, Sanofi-Genzyme, Pfizer, Eli Lilly.

Adam Friedman, MD, FAAD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speakers’ Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.

You May Also Like

Saving Skin, Hair & Nails with Supportive Oncodermatology: A Call to Action for All Those Involved

| Featured Podcast, Podcast Highlights | No Comments
iTunes Google Play Stitcher TuneIn Mario E. Lacouture, MD & Adam Friedman, MD, FAAD   While the old adage, "more oncology treatments, more skin problems," becomes more like dogma every…

AD Treatment – The Future Landscape

| Atopic Dermatitis, Featured Podcast, Podcast Highlights | No Comments
iTunes Google Play Stitcher TuneIn Drs. Amy Paller, Jonathan Silverberg & Adam Friedman   Consider this final episode of the 5 part all you can handle Atopic Dermatitis series the…

Perspectives on Managing Moderate-to-Severe Atopic Dermatitis

| Atopic Dermatitis, Featured Podcast, Podcast Highlights | No Comments
iTunes Google Play Stitcher TuneIn Drs. April Armstrong, Lawrence Eichenfield & Adam Friedman   The Ps of Lichen Planus got nothing on this alliteration filled podcast that was purposefully positioned…

Leave a Reply